Newsletter Vol. 11 HIV Program Update Enrolled First Cohort Since our last Newsletter, AGT has enrolled its first cohort of six participants in its Phase 1 study of AGT103-T against HIV. Updates on the RePAIR Clinical Trial (AGT103-T) Clinical Update [RePAIR = Restore Potent Antiviral Immune Responses] Video Summary by AGT’s Anisha Mannan, Sommar Nettles,… [Read More]
AGT Newsletter Volume 10
VOLUME 10 September 2020 Newsletter We’ve achieved a number of significant milestones this quarter, including the Food and Drug Administration (FDA) clearance to begin Phase 1 of our HIV cure program. The excitement hasn’t only been within our walls; AGT has appeared in publications and news stories across the country. The AGT Team’s commitment to our… [Read More]
AGT Newsletter Volume 9
VOLUME 9 May 2020 Newsletter FDA Progress The Path to the Clinic For the HIV Cure This month, AGT saw tremendous progress with the FDA. FDA time and attention to our project has seemed to increase while agency review responses to our submissions have narrowed to unambiguous guidance, helping the HIV cure enter clinical trials…. [Read More]
Happy New Year! AGT Newsletter – 2020 Edition
A STELLAR 2019 Has Positioned AGT For A SPECTACULAR 2020. I wanted to take a moment to sum up a great year of progress and success at AGT and to talk about potential milestones and significant inflection points in 2020. I’m sure you are aware that we filed the IND (investigations new drug) application for our HIV… [Read More]
AGT Newsletter Volume 8
Featured Stories AGT’s HIV cure program is nearing a major milestone: Investigational New Drug (IND) submission. The IND is the key document that reports the safety data the FDA requires prior to a human trial. If the document meets the expected criteria, AGT will be authorized to begin the phase I human trial. At this… [Read More]
AGT Newsletter Volume 7
Newsletter Vol. 7 In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry. Watch The Video 2018 has been a great year for American Gene Technologies: it added four new patents to its… [Read More]
AGT Newsletter Volume 6
NEWSLETTER VOL. 6 AGT’s progress over the first half of 2018 has been tremendous: six patents granted, major advances in all of its key projects: HIV, PKU and immuno-oncology, substantial momentum on social media with constant activity and announcements to thousands of followers, and huge growth in business development activities through outreach, events, and tradeshows. 2018 began with the… [Read More]
AGT Newsletter Volume 5
End of year wrap-up Q4, 2017 Newsletter AGT is in position for key milestones and success in 2018. 2017 brought attention to the industry and particularly to AGT. We raised nearly $8M (approximately double the previous year), and efficiently leveraged the capital to advance AGT’s key technologies and pre-clinical programs. Our recent work has yielded… [Read More]
AGT Newsletter Volume 4
AGT IN THE SPOTLIGHT American Gene Technologies International CEO, Jeff Galvin, is increasingly in demand for his thought leadership in addition to his vision for AGT. Jeff was invited to deliver the closing presentation at the June 13th HIMSS Precision Medicine Summit in Boston. He was also invited to join the morning leadership panel to… [Read More]
AGT Newsletter Volume 3
AGT CONTINUES TO GROW ITS TEAM AND RESOURCES INTERNALLY AND EXTERNALLY C. Neil Lyons AGT is announcing the appointment of C. Neil Lyons as Executive Vice President and Chief Financial Officer. Neil brings more than 30 years of experience in finance, strategy, capital, SEC compliance, and corporate governance in both public and private companies, and… [Read More]
AGT Newsletter Volume 2
Geovax announces a collaboration with AGT AGT and GeoVax Labs Inc. (OTCQB: GOVX) have announced a collaboration in preparation for a phase 1 clinical trial to test AGT’s HIV cure. This is the first announcement of several collaborations that will support testing the safety and feasibility of genetically modified CD4+T cells using our proprietary lentiviral… [Read More]
AGT Newsletter Volume 1
Building Momentum… We’ve kicked off 2017 with new intensity and excitement! AGT will be submitting our first Investigational New Drug (IND) application consistent with FDA’s great reception and feedback on our pre-IND application in November. We are on course to become a clinical stage biotech company in the 4th quarter of 2017. AGT”s executive team… [Read More]
